Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin (NASDAQ: AMRN) reported multiple new REDUCE-IT and mechanistic findings presented at ESC Congress 2026 in Munich, focused on treatment adherence, long-term outcomes, lipoprotein(a) [Lp(a)], coagulation biomarkers and pathways related to eicosapentaenoic acid (EPA) and icosapent ethyl (IPE).
Post hoc REDUCE-IT analyses described substantial variability in Lp(a) over 24 months, sex differences in study discontinuation, and reductions in tissue factor levels plus lower first cardiovascular event risk with icosapent ethyl in high-risk patients with elevated baseline tissue factor. Mechanistic work showed EPA limited Lp(a) oxidation and favorably modulated endothelial cell protein expression. Amarin also highlighted that new 2026 ESC/European Renal Association guidelines for cardiovascular disease and chronic kidney disease cite REDUCE-IT RENAL, reinforcing support for icosapent ethyl in statin-treated patients with elevated triglycerides and chronic kidney disease.
Amarin (NASDAQ:AMRN) reported new post hoc “REDUCE-IT Legacy” data presented at ESC Congress 2026, based on the REDUCE-IT® cardiovascular outcomes trial of 8,179 statin-treated, high‑risk patients with elevated triglycerides. Among 6,921 “high adherers” who stayed on icosapent ethyl (IPE) for at least 1.5 years, investigators observed approximately 29–30% relative risk reduction in the primary composite endpoint versus placebo, compared with 25% in the intention‑to‑treat population.
In a secondary prevention cohort of 1,318 patients who discontinued study drug after a mean 2.3 years, Kaplan‑Meier curves remained separated with a hazard ratio of 0.73 during total follow‑up and 0.73 after discontinuation, suggesting a potential “legacy” effect with no apparent loss of benefit over one to four years off therapy.
Amarin (NASDAQ: AMRN) announced multiple upcoming scientific presentations at the European Society of Cardiology (ESC) Congress 2026, held August 28–31 in Munich, Germany. The accepted abstracts expand evidence from the REDUCE-IT cardiovascular outcomes trial and related mechanistic research on icosapent ethyl/eicosapentaenoic acid (EPA).
Amarin-supported academic collaborators will present moderated posters on treatment adherence and “legacy” effects of high-dose EPA in high-risk patients, sex differences in early study discontinuation and drug withdrawal in REDUCE-IT, and post hoc analyses of coagulation biomarkers and their association with event-free survival. Additional work will examine how EPA influences oxidation of lipoprotein(a) [Lp(a)] and endothelial protein expression.
An oral presentation will address Lp(a) variability in high cardiovascular risk, hypertriglyceridemic patients on statins within REDUCE-IT. The release reiterates REDUCE-IT design, key VASCEPA/VAZKEPA indications, global approvals, and important U.S. safety information, including atrial fibrillation and bleeding risks.
Amarin (NASDAQ: AMRN) reported Q2 2026 total net revenue of $42.2 million, down 42% year over year, mainly due to the absence of the prior-year $25 million Recordati upfront payment and lower U.S./European product revenue under the partnered model. Net product revenue was $39.1 million, down 16%.
Operating expenses fell to $27.0 million (‑59%), or 38% lower excluding Q2 2025 restructuring, completing a $70 million annual cost-savings plan. Net loss improved to $7.7 million from $14.1 million, with operating margin at ‑28%. Cash increased to $314.6 million and the company remained debt-free, generating positive cash flow for the third straight quarter and targeting ~10% cash growth for full-year 2026.
Across partners, in‑market VASCEPA/VAZKEPA demand rose 59% year over year, with Europe up 69% and China in‑market volume up 90% year-to-date. U.S. IPE market share increased to 48% from 43%, with branded VASCEPA prescriptions up 14%. Amarin expects continued international growth, stable 2026 U.S. volumes, an improved operating expense profile and positive cash flow.
Amarin (NASDAQ: AMRN) will release its Q2 2026 financial results on Wednesday, July 29, 2026, in pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Investors can access the live call via U.S. dial-in 888-506-0062, international dial-in 973-528-0011 (access code 444188), or through a webcast on the Investor Relations section of Amarin's website.
A replay will be available by telephone at 877-481-4010 (U.S.) or 919-882-2331 (international), using replay code 54179, and via webcast replay on the Investor Relations section of the company's website until January 29, 2027.
Amarin (NASDAQ: AMRN) highlights the role of VASCEPA (icosapent ethyl) in treating severe hypertriglyceridemia (sHTG) amid new injectable APOC3 therapies. VASCEPA delivers a 33% median TG reduction, broad cardiovascular risk reduction, and guideline support, with an annual WAC of about $4,200 versus $40,000 for some injectables.
Amarin (NASDAQ: AMRN) reported new post hoc data from the REDUCE-IT placebo arm at the 2026 European Atherosclerosis Society Congress. In 3,485 statin-treated patients with elevated triglycerides followed for 4.9 years, risk-weighted apoB (RW-apoB) averaged about 30% higher than measured apoB and more effectively identified residual cardiovascular risk than LDL-C, non-HDL-C, or apoB.
Applying ESC intervention thresholds, RW-apoB classified more patients as high risk, suggesting potential value for improved risk stratification in routine care.
Amarin (NASDAQ: AMRN) reported Q1 2026 results: Total net revenue $45.1M (up 7% vs Q1 2025), product revenue $43.3M, licensing & royalties $1.8M (up 84%), and cash of $307.8M as of March 31, 2026. Operating expenses fell 31% to $29.1M; operating loss narrowed to $(11.3)M and net loss improved to $(10.5)M.
The company generated positive cash flow for a second consecutive quarter, reiterated expectation for full-year 2026 positive cash flow, and cited international partnership-driven European growth and updated clinical guidelines supporting icosapent ethyl.
Amarin (NASDAQ: AMRN) will report first quarter 2026 financial results and host a conference call on Wednesday, April 29, 2026.
The company will release results in pre-market hours and hold a live call at 8:00 a.m. ET, with telephone dial-in, webcast access on the Investor Relations website, and a replay available online until 10/29/26.
Amarin (NASDAQ: AMRN) highlighted ACC Scientific Sessions 2026 findings stressing that elevated triglycerides drive residual cardiovascular risk despite LDL-C control and that icosapent ethyl (IPE) can reduce events when added to statins.
Amarin-supported REDUCE-IT post hoc analysis found significant CV event reduction in extreme and very high-risk patients; plaque-imaging studies EVAPORATE and CHERRY showed favorable coronary plaque effects with EPA.